Cargando…
The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation....
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719355/ https://www.ncbi.nlm.nih.gov/pubmed/19383604 http://dx.doi.org/10.1074/jbc.M109.004952 |
_version_ | 1782170067739344896 |
---|---|
author | Podoly, Erez Shalev, Deborah E. Shenhar-Tsarfaty, Shani Bennett, Estelle R. Ben Assayag, Einor Wilgus, Harvey Livnah, Oded Soreq, Hermona |
author_facet | Podoly, Erez Shalev, Deborah E. Shenhar-Tsarfaty, Shani Bennett, Estelle R. Ben Assayag, Einor Wilgus, Harvey Livnah, Oded Soreq, Hermona |
author_sort | Podoly, Erez |
collection | PubMed |
description | The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation. Here, we report that BChE-K is inherently unstable as compared with the “usual” BChE (BChE-U), resulting in reduced hydrolytic activity and predicting prolonged acetylcholine maintenance and protection from AD. A synthetic peptide derived from the C terminus of BChE-K (BSP-K), which displayed impaired intermolecular interactions, was less potent in suppressing Aβ oligomerization than its BSP-U counterpart. Correspondingly, highly purified recombinant human rBChE-U monomers suppressed β-amyloid fibril formation less effectively than dimers, which also protected cultured neuroblastoma cells from Aβ neurotoxicity. Dual activity structurally derived changes due to the A539T substitution can thus account for both neuroprotective characteristics caused by sustained acetylcholine levels and elevated AD risk due to inefficient interference with amyloidogenic processes. |
format | Text |
id | pubmed-2719355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-27193552009-08-14 The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) Podoly, Erez Shalev, Deborah E. Shenhar-Tsarfaty, Shani Bennett, Estelle R. Ben Assayag, Einor Wilgus, Harvey Livnah, Oded Soreq, Hermona J Biol Chem Genomics, Proteomics, and Bioinformatics The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation. Here, we report that BChE-K is inherently unstable as compared with the “usual” BChE (BChE-U), resulting in reduced hydrolytic activity and predicting prolonged acetylcholine maintenance and protection from AD. A synthetic peptide derived from the C terminus of BChE-K (BSP-K), which displayed impaired intermolecular interactions, was less potent in suppressing Aβ oligomerization than its BSP-U counterpart. Correspondingly, highly purified recombinant human rBChE-U monomers suppressed β-amyloid fibril formation less effectively than dimers, which also protected cultured neuroblastoma cells from Aβ neurotoxicity. Dual activity structurally derived changes due to the A539T substitution can thus account for both neuroprotective characteristics caused by sustained acetylcholine levels and elevated AD risk due to inefficient interference with amyloidogenic processes. American Society for Biochemistry and Molecular Biology 2009-06-19 2009-04-21 /pmc/articles/PMC2719355/ /pubmed/19383604 http://dx.doi.org/10.1074/jbc.M109.004952 Text en © 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Author's Choice—Final version full access. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) applies to Author Choice Articles |
spellingShingle | Genomics, Proteomics, and Bioinformatics Podoly, Erez Shalev, Deborah E. Shenhar-Tsarfaty, Shani Bennett, Estelle R. Ben Assayag, Einor Wilgus, Harvey Livnah, Oded Soreq, Hermona The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) |
title | The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) |
title_full | The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) |
title_fullStr | The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) |
title_full_unstemmed | The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) |
title_short | The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) |
title_sort | butyrylcholinesterase k variant confers structurally derived risks for alzheimer pathology(♦) |
topic | Genomics, Proteomics, and Bioinformatics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719355/ https://www.ncbi.nlm.nih.gov/pubmed/19383604 http://dx.doi.org/10.1074/jbc.M109.004952 |
work_keys_str_mv | AT podolyerez thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT shalevdeborahe thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT shenhartsarfatyshani thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT bennettesteller thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT benassayageinor thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT wilgusharvey thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT livnahoded thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT soreqhermona thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT podolyerez butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT shalevdeborahe butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT shenhartsarfatyshani butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT bennettesteller butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT benassayageinor butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT wilgusharvey butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT livnahoded butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology AT soreqhermona butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology |